Building Companies at the Edge of Science and Market - Life Sciences Today Podcast Episode 61

Why It Matters

Ernst’s rapid, network‑driven launch demonstrates that deep‑tech founders can compress medical‑device timelines and secure market traction, offering a blueprint for future bio‑electronics startups facing funding and regulatory hurdles.

Key Takeaways

• Interdisciplinary background bridges deep tech and life‑science markets
• Built FDA‑cleared neuromodulation device in three years with $3M
• Leveraged network to secure neuroscientist and physician advisors quickly
• COVID‑era launch forced pivot to OTC, limiting iterative product upgrades
• Public listing used to raise capital after supply‑chain and funding challenges

Summary

The Life Sciences Today podcast features Jennifer Ernst, a rare hybrid who has moved from high‑tech device work at Xerox PARC to bio‑electronic medicine. Her career is defined by matching breakthrough science with clear market opportunities, from printed‑electronics roll‑to‑roll manufacturing to chairing a government‑backed flexible electronics consortium.

Ernst describes how she assembled a small team around a handheld neuromodulation device—later branded Clearup—turning a quirky prototype that resembled a rectal thermometer into an FDA‑cleared product in just three years and under $3 million. She leveraged her extensive network to recruit a neuroscientist who identified the norepinephrine‑triggering mechanism and a physician advisor who guided trial design, enabling rapid patient recruitment at Stanford.

Key anecdotes illustrate her unconventional approach: “It looked like a rectal thermometer for a cow,” she jokes, and she notes that regulators treated the device almost like a handshake because of its negligible current. Early consumer research showed 85 % of users preferred a simple, non‑connected device, shaping the product’s minimal‑viable design.

The story underscores how interdisciplinary expertise, strategic networking, and agile pivots—especially the shift to an over‑the‑counter model during COVID‑related supply constraints—can accelerate medical‑device commercialization. Ernst’s later decision to take the company public highlights a path for raising capital when traditional venture funding dries up.

Original Description

We're excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Jennifer Ernst, Co-Founder and CEO at Valion Bio (formerly Tivic Health). Ernst has built companies at the intersection of breakthrough science and market opportunity — from Xerox PARC’s open innovation lab to printed electronics to bioelectronic medicine.

As Co-Founder of Valion Bio, she took a handheld neuromodulation device from idea to FDA clearance in three years for under $3M, took the company public on Nasdaq, and executed a bold pivot into biopharmaceuticals. 

In this episode, we dig into the hardest question in neuromodulation today: getting FDA approval is like base camp at Everest, and getting paid is reaching the summit — how do you get from base camp to the summit? And Ernst shares her remarkable journey from Xerox PARC to pioneering bioelectronic medicine — and what it really takes to build a business in neuromodulation.

For more great episodes of our Life Sciences Today Podcast, check out: https://www.healthcareittoday.com/category/life-sciences-today-podcasts/